RT @Abdallah81MD: Bispecific Antibodies in Multiple Myeloma: Present and Future https://t.co/CmQnT7nBjh #mmsm #myeloma #medtwitter #MedEd…
RT @Abdallah81MD: Bispecific Antibodies in Multiple Myeloma: Present and Future https://t.co/CmQnT7nBjh #mmsm #myeloma #medtwitter #MedEd…
RT @Abdallah81MD: Bispecific Antibodies in Multiple Myeloma: Present and Future https://t.co/CmQnT7nBjh #mmsm #myeloma #medtwitter #MedEd…
RT @Abdallah81MD: Bispecific Antibodies in Multiple Myeloma: Present and Future https://t.co/CmQnT7nBjh #mmsm #myeloma #medtwitter #MedEd…
RT @Abdallah81MD: Bispecific Antibodies in Multiple Myeloma: Present and Future https://t.co/CmQnT7nBjh #mmsm #myeloma #medtwitter #MedEd…
RT @Abdallah81MD: Bispecific Antibodies in Multiple Myeloma: Present and Future https://t.co/CmQnT7nBjh #mmsm #myeloma #medtwitter #MedEd…
Helpful slide. Thanks @Abdallah81MD #myeloma
RT @Abdallah81MD: Bispecific Antibodies in Multiple Myeloma: Present and Future https://t.co/CmQnT7nBjh #mmsm #myeloma #medtwitter #MedEd…
RT @Abdallah81MD: Bispecific Antibodies in Multiple Myeloma: Present and Future https://t.co/CmQnT7nBjh #mmsm #myeloma #medtwitter #MedEd…
RT @Abdallah81MD: Bispecific Antibodies in Multiple Myeloma: Present and Future https://t.co/CmQnT7nBjh #mmsm #myeloma #medtwitter #MedEd…
RT @Abdallah81MD: Bispecific Antibodies in Multiple Myeloma: Present and Future https://t.co/CmQnT7nBjh #mmsm #myeloma #medtwitter #MedEd…
RT @Abdallah81MD: Bispecific Antibodies in Multiple Myeloma: Present and Future https://t.co/CmQnT7nBjh #mmsm #myeloma #medtwitter #MedEd…
RT @Abdallah81MD: Bispecific Antibodies in Multiple Myeloma: Present and Future https://t.co/CmQnT7nBjh #mmsm #myeloma #medtwitter #MedEd…
RT @Abdallah81MD: Bispecific Antibodies in Multiple Myeloma: Present and Future https://t.co/CmQnT7nBjh #mmsm #myeloma #medtwitter #MedEd…
Bispecific Antibodies in Multiple Myeloma: Present and Future https://t.co/CmQnT7nBjh #mmsm #myeloma #medtwitter #MedEd #USMIRC @USMIRCNEWS https://t.co/JzkpDQlQKz
RT @_TanyaBondar_: FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma https://t.co/XqDoD9Zasc The first #Bispecifi…
RT @_TanyaBondar_: FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma https://t.co/XqDoD9Zasc The first #Bispecifi…
FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma https://t.co/XqDoD9Zasc The first #BispecificAntibody approval for #multiplemyeloma! Many other BiTEs are being developed, as recently reviewed by @ajaichari https://t.co/kEaB08G
Bispecific antibody takes the stage at #IMS2022! Read the recent review on bispecific therapies for #myeloma, by @AjaiChari et al. https://t.co/KElJMoKhiB https://t.co/qYnkVxdDVx
RT @BCD_AACR: #ICYMI: Bispecific Antibodies in #MultipleMyeloma: Present and Future by Lancman, @AjaiChari et al. https://t.co/XtcbRSLUoj @…
#ICYMI: Bispecific Antibodies in #MultipleMyeloma: Present and Future by Lancman, @AjaiChari et al. https://t.co/XtcbRSLUoj @IcahnMountSinai #MultipleMyelomaAwarenessMonth #mmsm #immunotherapy #immunooncology #bispecificantibody https://t.co/AGA6VJQKvC
RT @HJChoMDPhD1: Due credit to our outstanding Fellow Guido Lancman and his mentor MMRC Steering Committee Member Ajai Chari!
PC | Bispecific Antibodies in Multiple Myeloma: Present and Future https://t.co/54VcusW3eM
RT @Transplant_Doc: Bispecific Antibodies in Multiple Myeloma: Present and Future #mmsm @BCD_AACR https://t.co/5L6XluN6V5
Bispecific Antibodies in Multiple Myeloma: Present and Future #mmsm @BCD_AACR https://t.co/5L6XluN6V5
RT @BCD_AACR: From the September issue - Bispecific Antibodies in Multiple Myeloma: Present and Future. https://t.co/UURg8pyROL @AjaiChari…
From the September issue - Bispecific Antibodies in Multiple Myeloma: Present and Future. https://t.co/UURg8pyROL @AjaiChari @IcahnMountSinai #mmsm #immunotherapy #immunooncology #bispecificantibody https://t.co/5GttFkXioK
RT @SinaiHemeOnc: 📰alert: Congratulations to our fellow Guido Lancman and @TischCancer @IcahnMountSinai Myeloma Ctr Excellence docs for the…
RT @SinaiHemeOnc: 📰alert: Congratulations to our fellow Guido Lancman and @TischCancer @IcahnMountSinai Myeloma Ctr Excellence docs for the…
📰alert: Congratulations to our fellow Guido Lancman and @TischCancer @IcahnMountSinai Myeloma Ctr Excellence docs for their review paper in @BCD_AACR https://t.co/dQ73uD29E6. 👏 @AjaiChari @HJChoMDPhD1 @DMadduri @JoshuaRichterMD, Drs. Jagannath, Parekh, Ric
RT @TischCancer: Bispecific Antibodies in #MultipleMyeloma: Present and Future https://t.co/MUhANX17qG @HJChoMDPhD1 @AjaiChari @JoshuaRich…
RT @HadidiSamer: Bispecific Antibodies in MM:Present and Future @BCD_AACR @AACR #mmsm ➡️Link:https://t.co/p3zA8impQ6 ➡️ a nicely written r…
RT @HadidiSamer: Bispecific Antibodies in MM:Present and Future @BCD_AACR @AACR #mmsm ➡️Link:https://t.co/p3zA8impQ6 ➡️ a nicely written r…
RT @HadidiSamer: Bispecific Antibodies in MM:Present and Future @BCD_AACR @AACR #mmsm ➡️Link:https://t.co/p3zA8impQ6 ➡️ a nicely written r…
RT @HadidiSamer: Bispecific Antibodies in MM:Present and Future @BCD_AACR @AACR #mmsm ➡️Link:https://t.co/p3zA8impQ6 ➡️ a nicely written r…
Bispecific Antibodies in MM:Present and Future @BCD_AACR @AACR #mmsm ➡️Link:https://t.co/p3zA8impQ6 ➡️ a nicely written review on Bispecifics in MM,many in development, promising agents ➡️ ORR for all ~ 60-80%, heavily pre-ttt, short follow up so far ➡️
RT @BCD_AACR: From the September issue: Bispecific Antibodies in Multiple Myeloma: Present and Future. https://t.co/WsQQEN643J. @AjaiChari…
From the September issue: Bispecific Antibodies in Multiple Myeloma: Present and Future. https://t.co/WsQQEN643J. @AjaiChari @IcahnMountSinai #mmsm #immunotherapy #immunooncology #bispecificantibody https://t.co/VFId0mvc1W
RT @TischCancer: Bispecific Antibodies in #MultipleMyeloma: Present and Future https://t.co/MUhANX17qG @HJChoMDPhD1 @AjaiChari @JoshuaRich…
Bispecific Antibodies in #MultipleMyeloma: Present and Future https://t.co/MUhANX17qG @HJChoMDPhD1 @AjaiChari @JoshuaRichterMD @DMadduri
RT @theMMRF: Nice review of bispecific antibodies in #myeloma by our CMO @HJChoMDPhD1, @DMadduri, @JoshuaRichterMD and others @TischCancer…
RT @theMMRF: Nice review of bispecific antibodies in #myeloma by our CMO @HJChoMDPhD1, @DMadduri, @JoshuaRichterMD and others @TischCancer…
RT @theMMRF: Nice review of bispecific antibodies in #myeloma by our CMO @HJChoMDPhD1, @DMadduri, @JoshuaRichterMD and others @TischCancer…
RT @theMMRF: Nice review of bispecific antibodies in #myeloma by our CMO @HJChoMDPhD1, @DMadduri, @JoshuaRichterMD and others @TischCancer…
RT @theMMRF: Nice review of bispecific antibodies in #myeloma by our CMO @HJChoMDPhD1, @DMadduri, @JoshuaRichterMD and others @TischCancer…
Due credit to our outstanding Fellow Guido Lancman and his mentor MMRC Steering Committee Member Ajai Chari!
RT @theMMRF: Nice review of bispecific antibodies in #myeloma by our CMO @HJChoMDPhD1, @DMadduri, @JoshuaRichterMD and others @TischCancer…
RT @theMMRF: Nice review of bispecific antibodies in #myeloma by our CMO @HJChoMDPhD1, @DMadduri, @JoshuaRichterMD and others @TischCancer…
RT @BCD_AACR: #OnlineFirst— Bispecific Antibodies in Multiple Myeloma: Present and Future. @AjaiChari @IcahnMountSinai #mmsm #immunotherapy…
Nice review of bispecific antibodies in #myeloma by our CMO @HJChoMDPhD1, @DMadduri, @JoshuaRichterMD and others @TischCancer and @IcahnMountSinai. Bispecifics are likely to become part of the myeloma treatment paradigm in the near future. #mmsm https://
RT @BCD_AACR: #OnlineFirst— Bispecific Antibodies in Multiple Myeloma: Present and Future. @AjaiChari @IcahnMountSinai #mmsm #immunotherapy…
RT @BCD_AACR: #OnlineFirst— Bispecific Antibodies in Multiple Myeloma: Present and Future. @AjaiChari @IcahnMountSinai #mmsm #immunotherapy…
#OnlineFirst— Bispecific Antibodies in Multiple Myeloma: Present and Future. @AjaiChari @IcahnMountSinai #mmsm #immunotherapy #immunooncology #bispecificantibody https://t.co/geRJGpoqR7 https://t.co/BKpHcCmeYf